Prakt. Lékáren. 2016; 12(6e): e23-e30 | DOI: 10.36290/lek.2016.089

Phytotherapy in the treatment of benign prostatic hyperplasia – present state i Czech Republic

Luboslav Stárka, Lucie Kolátorová Sosvorová
Endokrinologický ústav

Among the facilities for the treatment of the symptoms of benign prostatic hyperplasia (BPH) herbal preparations are used by millions of menaffected by BPH, though these drugs are not recommended by urological societies due to lack of compliance with the requirements of the medicineof evidence. The results with herbal pharmacy announced in the older literature have a low validity due insufficient standardisation of thepreparations and due to the weak design of the studies. In well-designed studies some positive effects on the low urinary tract syndrome (LUTS) were shown, however, these did not differ dramatically from the effects of placebo. Among the herbal drugs obtainable in our pharmacies themost frequent main component is the extract from saw palmetto (Serenoa repens), which is also the most popular in other countries. With exceptionof three herbal drugs, which are registered by State Institute of Drug Control (SÚKL), the remaining 23 are listed as dietary supplements.

Keywords: benign prostatic hyperplasia, herbal preparations, Serenoa repens, Pygeum africanum, Curcubita pepo, Urtica dioica, Epilobium parviflorum

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stárka L, Kolátorová Sosvorová L. Phytotherapy in the treatment of benign prostatic hyperplasia – present state i Czech Republic. Praktické lékárenství. 2016;12(E-verze 6/16):e23-30. doi: 10.36290/lek.2016.089.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Veselský Z. Význam fytoterapie u nemocných s benigní hyperplasií prostaty. Urologie pro praxi 2006; 7(5): 220-225.
    2. Porš J, Kolombo I, Poršová M. Fytopreparáty v léčbě benigní hyperplasie prostaty, Urologie pro praxi 2009; 10(1): 22-24.
    3. Stárka L, Sosvorová L, Mikšátková P. Herbální přípravky používané při léčbě benigní hyperplazie prostaty. Urologie pro praxi 2012; 13(6): 239-244.
    4. Jezdinský J. Komentář. Urologie pro praxi 2012; 13(6): 244-245.
    5. Tůmová L. Serenoa repens - terapeutické účinky a možné interakce. Praktické lékárenství. 2011; 7(2): 86-86.
    6. Alikanjari O, Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci 2015; 126: 42-56. Go to original source... Go to PubMed...
    7. Keehn A, Taylor J, Lowe FC. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep 2016; 17: 53. Go to original source... Go to PubMed...
    8. Hill B, Kyprianou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. Prostate 2004; 61(1): 73-80. Go to original source... Go to PubMed...
    9. Cao N, Haynes JM, Ventura S. Saw palmetto is an indirectly acting sympathomimetic in the rat-isolated prostate gland. Prostate 2006; 66(2): 115-123. Go to original source... Go to PubMed...
    10. Ricco J, Prasad S. The shinking case of saw palmetto. J Pharm Pract 2012; 61(7): 418-420.
    11. Booker A, Suter A, Krnjic A, Strassel B, Zloh M, Said M, Heinrich M. A phytochemical comparison of saw palmetto products using gas chromatography and (1) H nuclear magnetic resonance spectroscopy metabolomic profiling. J Pharm Pharmacol 2014; 66(6): 811-822. Go to original source... Go to PubMed...
    12. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009; 32(8): 637-647. Go to original source... Go to PubMed...
    13. Azimi H, Khakshur AA, Aghdasi I, Fallah-Tafti M, Abdollahi M. A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets 2012; 11(3): 207-221. Go to original source... Go to PubMed...
    14. Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy. Complement Ther Med. 2013; 21(3): 172-179. Go to original source... Go to PubMed...
    15. Ishani A, Macdonald R, Nelson D, Rutks I, Wilt TJ. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 2000; 109(8): 654-664. Go to original source... Go to PubMed...
    16. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (1): CD001044 Go to original source...
    17. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries, Eur Urol 2007; 51(1): 207-215. Go to original source... Go to PubMed...
    18. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother 2005; 5(4): 1-11. Go to original source...
    19. Schneider T, Rübben H, Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, doubleblind, placebo controlled multicenter study after 12 months, Urologe A 2004; 43(3): 302-306. Go to original source... Go to PubMed...
    20. Xu J, Qian WQ, Song JD. A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia. Zhonghua Nan Ke Xue 2008; 14(6): 533-537. Go to PubMed...
    21. Kim SK, Seok H, Park HJ, et al. Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complement Altern Med 2015; 15: 380. Go to original source... Go to PubMed...
    22. Ammar AE, Esmat A, Hassona MD, Tadros MG, Abdel-naim AB, Guns ES. The effect of pomegranate fruit extract on testosterone induced BPH in rats. Prostate 2015; 75(7): 679-692. Go to original source... Go to PubMed...
    23. Said MM, Hassan NS, Schlicht MJ, Bosland MC. Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia. J Toxicol Environ Health A 2015; 78(7): 453-465. Go to original source... Go to PubMed...
    24. Chun Ho Ma, Wai Ling Lin, Sing Leung Lui, Xun-Yuan Cai, Vivian Taam Wong, Eric Ziea, Zhang-Jin Zhang. Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials. Asian J Androl 2013; 15(4): 471-482. Go to original source... Go to PubMed...
    25. Shrivastava A, Gupta VP. Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health 2012; 3(1): 10-19. Go to original source... Go to PubMed...
    26. Papaioannou M, Schleich S, Roell D, Schubert U, Tanner T, Claessens F, Matusch R, Baniahmad A. NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. Invest New Drug 2010; 28(6): 729-743. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.